Login to Your Account

Teva give-back puts cell-based heart failure therapy in Mesoblast's hands

By Michael Fitzhugh
Staff Writer

Tuesday, June 14, 2016

Mesoblast Ltd. lost more than a third of its market value Tuesday as Teva Pharmaceutical Industries Ltd. returned full development and commercialization rights to its advanced chronic heart failure therapy, MPC-150-IM.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription